Purpose: The clinical significance of VEGF-A expression in gastric cancer (GC) has been reported with contradicting results. We analyzed the expression and clinical significance of VEGF-A in a wide Italian cohort of GC specimens. Methods: VEGF-A expression was tested by immunohistochemistry in 507 patients with GC of all clinical stages. The impact of VEGF-A on overall survival (OS) was evaluated in conjunction with clinical and pathological parameters. Results: In the Italian cohort we studied VEGF-A was not an independent prognostic factor neither at the univariate nor at multivariate analysis. Conclusions: Although frequently expressed, in our study VEGF-A was not able to discriminate between groups of patients with different risk.
Introduction
GC is the fourth most common cancer and the second leading cause of cancer-related death worldwide. 1 The vast majority of GC are adenocarcinomas; they are diagnosed after they have invaded the muscularis propria and are therefore classified as Advanced Gastric Cancers (AGC). The detection of a GC which is still confined to the mucosa and submucosa (Early Gastric Cancer, EGC) leads to a better prognosis. 2 It has been demonstrated that GC incidence and mortality show geographic variability and Europe has an intermediate incidence rate, between high incidence countries (such as Japan) and low incidence countries (African countries). 3 Despite earlier diagnosis, radical surgery and the development of novel adjuvant therapies, including target therapies, have improved prognosis for GC, the 5-years survival rate, across all the TNM stages, is only about 28%, based on data provided by the American Cancer Society. Moreover, Japanese survival rates are higher than those observed in Western countries and within Europe, consistent differences can be observed. 4 Standard chemotherapy, both in resectable and advanced disease, has however limited efficacy. Hence, the identification of novel molecular markers, as well as new cancerogenetic mechanisms and targets for therapeutic interventions, are urgently needed to improve prognosis.
A relevant aspect of tumor growth is represented by intratumoral angiogenesis. It has been hypothesized that cancer cells begin to promote angiogenesis early in tumorigenesis. This early "angiogenic switch" 5 is characterized by oncogene-driven tumor expression of pro-angiogenic proteins. 6 Among them, the Vascular Endothelial Growth Factor-A (VEGF-A) is one of the most relevant angiogenic factors, 7 whose expression is regulated by both oxygen tension 8 and polypeptide growth factors, cytokines, as well as oncogenic mutations of relevant intracellular signaling components (reviewed in Ref. 9 ). VEGF-A and its receptors have been identified to critically influence tumor-related angiogenesis, in several cancer types, including GC. 10 VEGF-A impact on prognosis has been demonstrated by meta-analysis in different cancers such as hepatocellular 11 and pancreatic cancer. 12 Despite numerous studies, however, the prognostic significance of VEGF expression in GC is still under debate 13e21 and an extensive meta-analysis has been recently published 22 showing that ethnicity is a predictive factor of the effect of VEGF-A on prognosis.
Very few papers evaluating VEGF-A clinical significance in big cohorts of non-Asian individuals have been published so far. The majority of the studies analyzed Asian patients whose pathological characteristics are quite different from those of Western countries' subjects. Indeed, from a comparison between a Japanese and a British cohort 23 it emerged a prevalence of Lauren's intestinal type in European patients, and of diffuse type in Japanese subjects. Moreover, the Japanese cohort showed high percentages of TNM stage I and II with respect to stages III and IV, while in the British cohort the distribution was more homogeneous.
The present paper was aimed at better defining the expression profile and prognostic role of VEGF-A in a wide Italian cohort of GC samples, encompassing all pathological stages.
Materials and methods

Patients and tissue specimens
Tissue samples (n ¼ 190) were prospectively obtained after informed written consent from patients who underwent surgery with curative or palliative intent for primary gastric cancers at the Department of Surgery and Translational Medicine, University of Florence and the General Surgery and Surgical Oncology, Azienda Ospedaliero-Universitaria, Careggi, Florence, Italy. Patients affected by viral hepatitis or who had undergone pre-operative radiotherapy or chemotherapy were excluded from the study. Samples were taken in the operating room and a sample of paired normal gastric mucosa was collected from the operative specimens at least 10 cm from the tumor, and from the same region of the stomach containing the tumor, when applicable.
Moreover, a multicenter cohort of GC archival samples Diagnosis and histological grading were assessed in all cases using standard criteria by experienced pathologists (LM, AT, CV, and LS). The study population was represented by 508 patients with complete follow up information.
Immunohistochemistry (IHC)
Due to the broad expression of VEGF-A in stromal cells of the gastric submucosa 24 that might raise false positive results with standard molecular techniques, VEGF-A expression was retrospectively tested by IHC, and performed as previously reported 25 using anti-VEGF-A antibody (Polyclonal antibody anti VEGF-A (A-20), Santa Cruz Biotechnology; Santa Cruz CA, USA, 1: 100 dilution). As a preliminary step, we validated the antibody performing Western Blot assays and immunocytochemistry (see below) and optimized the IHC procedure 25 in different primary tissues (high grade astrocytomas, renal tissue and normal colorectal tissue), that served as positive internal controls for VEGF-A staining. The staining background due to the expression of VEGF-A in stromal and inflammatory cells was considered as non-specific staining. Nevertheless, while evaluating the immunohistochemistry results only positive tumor cells were considered. Negative controls (no primary antibody) were included in each IHC experiment. After dewaxing and dehydrating the sections, endogenous peroxidases were blocked with a 1% H 2 O 2 solution in PBS. Subsequently, antigen retrieval was performed with Proteinase K (5 mg/ml) Because of the intracellular localization of the antigens, tissue permeabilization was required, therefore treatment with blocking solution and permeabilization were carried out (Ultra V Block containing 0.1% Triton X100, LabVision; Fremont CA, USA). Antibodies were incubated overnight at 4 C. Immunostaining was performed with a commercially available kit (PicTure Max kit, Invitrogen; Carlsbad CA, USA) according to manufacturer's instructions. Stained sections were analyzed at a total magnification of 40Â field by field, from top left to bottom right. A significant VEGF-A labeling was detected in GC samples where the protein was mainly expressed in the cytoplasm of cancerous epithelial cells, with a low expression in the tumor stroma. To evaluate the VEGF-A status of the samples, only epithelial-derived tumor cells were taken into account, while the signal detected in stromal or inflammatory cells was not considered. VEGF-A was scored as the number of positive tumor cells over total tumor cells, first setting the threshold value, using different cut offs. Percentage scores were then categorized using the 0% cutoff (0% staining vs any staining), the 10% cutoff (<10% tumor cell staining vs !10%), the 25% (<25% tumor cell staining vs !25%) and the 50% (<50% tumor cell staining vs !50%). Since the vast majority of the samples belonged to the highest score categories, no substantial difference emerged in the three cut off values groups (10%, 25%, 50%). In particular, the percentages of low score samples were 12.3%, 14.2% and 16.1% (with <10%, <25% and <50% cut-offs, respectively) while high score samples were 87.7%, 85.8% and 83.9% (with >10%, >25% and >50% cut offs, respectively). We argued that no significant biological differences characterized the different scoring groups. Hence, assignment of a positive score was performed when the sample showed more than 10% positive cells according to Galizia et al., 2004 26 and as previously reported by other groups and by us. 17, 25 Results were evaluated by two independent investigators (EL and MRR). A third joint observation with conclusive agreement as well as the independent review of the slides by a third observer (SB) was performed. When needed, an additional review by experienced pathologists of each participating center was performed. Interobserver agreement was evaluated according to the simple Cohen's k of concordance and its 95% confidence interval.
Western Blot (WB)
Diluted serum samples were heated in reducing Laemmli buffer (6.25 mM Tris-HCl pH 6.8, 1% glycerol, 2% SDS, 2% b-mercaptoethanol and 0.0012% bromophenol blue) at 95 C for 5 min, separated by 10% SDS-PAGE and transferred to a PVDF membrane (Amersham). After transfer, the membrane was blocked for 2 h at room temperature with PBS þ Tween-20 0.1% (T-PBS), containing 5% BSA (T-PBS-BSA) and incubated overnight at 4 C with anti-VEGF-A antibody (A-20, Santa Cruz Biotechnology), diluted 1:500 in T-PBS-BSA. The membrane was then washed 3 times with T-PBS and incubated with anti-rabbit peroxidase-conjugated secondary antibody (Sigma) diluted 1:10,000 in T-PBS-BSA for 45 min at room temperature. After 3 washes with T-PBS, the membrane was revealed by a chemiluminescent reaction with ECL (Amersham). 
Immunocytochemistry (ICC)
ICC was performed on HCT116 cell line. Cells were cultured in RPMI 1640 (Euroclone) supplemented with 10% Fetal Calf Serum (Euroclone) and 2 mM L-Glutamine. Cells were grown on glass coverslips, washed twice in PBS and fixed in 90% ethanol for 10 min at room temperature with gentle agitation. Coverslips were then air-dried and stored at room temperature. For ICC experiments, coverslips were treated with 0.1% H 2 O 2 for 15 min at room temperature, to ensure endogenous peroxidases blocking and then incubated with Ultra Vision Protein Block solution (Fisher Scientific) with 0.1% Triton X-100 for 20 min at room temperature. Cells were then incubated with anti-VEGF-A antibody (A-20, Santa Cruz Biotechnology) diluted 1:100 in PBS-Ultra Vision Protein Block (10:1, v/ v) for 2 h at room temperature. Immunostaining was carried out with PicTure Max kit and DAB (Invitrogen). For negative control samples, no primary antibody was added to the PBS-Ultra Vision Protein Block solution. Coverslips were then counterstained with Mayer Hematoxylin and mounted on glass slides.
Statistical analysis
The distributions of all studied patients were reported with respect to their demographic, clinical, and biologic characteristics and were summarized as frequencies and percentage. Continuous variables were reported as median and range of variation. To avoid the exclusion of cases with missing data, the multiple imputation method was used (10 imputations). Logistic regression and regression methods were used for imputation of categorical and continuous variables, respectively. Missing-at-random assumptions were made. The following demographic, clinical and biological variables were investigated: age at the intervention, gender, site of primary, TNM stage, pathological grading, Lauren type and VEGF-A status. Both in the association and survival analyses, age was categorized in two groups (<70 years vs !70 years). As a measure of the strength of the association between the VEGF-A expression and each other characteristics, the odds ratio (OR) value and its 95% confidence interval (CI) was estimated with a univariate logistic regression model, combining the results of the analyses of imputations. The statistical significance of odds ratios was evaluated according to the likelihood ratio test. All the variables were investigated for their impact on overall survival (OS). OS was defined as the time between intervention and death, whatever the cause. Observation time of patients alive at the last follow-up visit was censored. Median follow-up time was estimated according to the KaplaneMeier inverse method. 27 Univariate and multivariate hazard ratios (HRs) estimates, and appropriate 95% CIs, were calculated by means of the Cox proportional hazard model, combining the results of the analyses of imputations. The statistical significance of HRs was evaluated according to the likelihood ratio test. The multivariate Cox regression model was fitted including in the model all the investigated parameters. The presence of interaction on OS between the VEGF-A status and other characteristics was verified with the interaction test. A two-sided P 0.05 was considered significant in all analyses. No adjustment for multiple comparisons was made. Statistical analyses were performed by LB using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Characteristics of study cohort
Patients were enrolled from different Italian centers (Florence, Verona, Siena and Forl ı). As shown in Table 1 the group of 71 patients excluded from analysis did not significantly differ from the study population. Patient samples encompassed all TNM stages, with higher percentages in stages III and IV. As it can be observed from Table 1 , a slight prevalence of males and G3 pathological grade characterized the cohort under study. Moreover, 63.8% of the samples were classified as Lauren's intestinal type, according to the most frequent histotype in Italy. 28 To confirm the specificity of anti-VEGF-A antibody, preliminary experiments were performed. In particular, Western Blot assay was performed on human serum samples with high VEGF-A levels (previously determined by Human VEGF Quantikine ELISA kit). As shown in Fig. 1A , WB results indicate that anti-VEGF-A antibody specifically binds VEGF-A monomer in reduced serum samples, in which a band of about 24 kDa is evident, according to the product's datasheet.
To further confirm the antibody specificity, ICC experiments were carried out on HCT116 cell line, already characterized for VEGF-A secretion. 29 In Fig. 1B The expression of VEGF-A in primary GC was studied only by IHC, due to the broad expression of VEGF-A in stromal cells of the gastric submucosa. 24 Normal gastric mucosa did not express the protein (Fig. 2, panels A  and B) , while a low expression was observed in the stroma (more evident in panel B), as expected. When analyzing tumor samples a significant VEGF-A labeling was detected in GC samples of Lauren's intestinal type (Fig. 2 , panels C and D) where the protein was mainly expressed in the cytoplasm of cancerous epithelial cells, while nuclei were negative, as expected. A lower expression of the protein was observed in the tumor stroma (Fig. 2D) . Samples of the diffuse type turned out to be negative (Fig. 2 , panels E and F). A positive score for VEGF-A was assigned when the sample showed more than 10% positive cells. 26 On the whole, 87.7% of the samples expressed VEGF-A with a high immunoreactivity score. No associations between clinicalepathological parameters and VEGF-A expression emerged ( Table 2) .
The samples were evaluated by two independent investigators and the k value related to the interobserver measure of agreement was 0.92 (95% CI: 0.85e0.99). 
Prognostic markers evaluation
After a median follow-up of 11.1 years (IQR: 7.3e15.0) 391 deaths were observed.
At the univariate analyses, age !70 years, male sex, site (gastric stump and linitis plastica), advanced stages and diffuse/mixed Lauren were associated with a worse prognosis (Table 3) . On the contrary, VEGF-A did not show any impact on overall survival (OS) (HR ¼ 1.00, 95% CI: 0.59e1.68; P ¼ 0.510). From the comparison of early-onset GC ( 45 years) with late-onset GC (>45 years) no statistically significant results emerged, due to the quite low percentage of patients belonging to the early-onset group (only 5%).
The multivariate analysis confirmed the results obtained at the univariate analysis (Table 3) .
Finally, one statistically significant interaction on OS was observed between pathological grading and VEGF expression (P ¼ 0.001) although not clinically relevant, with an HR ¼ 1.07 in G1eG2 samples and a HR ¼ 0.95 in G3eG4 samples (Fig. 3) .
Discussion
In the present paper we evaluated VEGF-A expression and clinical significance in a huge cohort of non-Asian individuals suffering from GC. In particular, VEGF-A expression was analyzed in a large series of GC patients all belonging to Italian ethnicity, using methodologies and antibodies employed in different Research and Medical Centers. 17, 25 Study population was characterized by a slight prevalence of males, G3 pathological grading and TNM stages III and IV. As expected, 28 the intestinal Lauren's histological type prevailed. In our series, VEGF-A expression was not associated with clinico-pathological characteristics and had no impact on overall survival. A statistically significant interaction on OS was observed between pathological grading and VEGF expression, although not clinically relevant. It should be also noted that in our series VEGF-A is expressed by the majority of samples (87.7%) and this imbalance makes it quite difficult to draw precise correlations.
To our knowledge a very few papers evaluating the prognostic value of VEGF-A in big cohorts of non-Asian individuals have been published so far. In fact, the majority of the studies analyzed Asian patients, whose pathological characteristics are quite different from those of Western countries' subjects. In this case, data concerning VEGF-A prognostic impact mainly address it as a negative factor. 13, 14, 16, 19, 21 Only a paper, reporting data obtained in a big cohort of patients, found no association between VEGF-A expression and prognosis in GC evaluated by IHC using paraffin-embedded samples, 18 in agreement with our findings. Moreover, a meta-analysis whose results have been published in 2012, 22 showed that VEGF-A expression is associated with poor prognosis in Asian population, while this correlation is lacking in non-Asian cohorts.
Similarly to the present, the study conducted by Lieto et al. 17 investigated the prognostic impact of VEGF-A expression in patients of Italian origin, although reaching a different conclusion. This discrepancy could be traced back to the fact that Lieto et al. analyzed a smaller number (88 vs 508) of patients, with different clinico-pathological characteristics, such as a higher percentage of diffuse type cases.
From this scenario, and our data support this hypothesis, it emerges that VEGF-A expression has a negative prognostic impact only in Asian GC patients, 16,17,30e33 with low or null impact in Western country populations.
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